What Exactly is LL-37 (CAP-18):
Antimicrobial peptide LL-37 (also known as CAP-18) is the only human cathelicidin to date. Toxic to bacteria and potentially harmful to viruses, the LL-37 peptide is predominantly located in polymorphonuclear leukocytes and macrophages.
Researchers believe that LL37 could be a viable antibiotic replacement because of its remarkable ability to reduce the number of bacteria in the body. In addition, one study found antimicrobial activity against many different human pathogenic gram-positive and harmful bacteria, suggesting that Cathelicidin 37 may help treat infections.
AMPs such as LL 37, according to new research, are critical in wound healing, cancer treatment, and autoimmune disease prevention.
What is LL-37 (CAP-18) Known For?
Antibacterial peptide LL-37 is currently the subject of extensive research by scientists. The peptide has so far been found to have several health benefits.
An immune system component, LL-37 attaches to the gram-negative bacteria’s lipopolysaccharide (LPS) and interferes with it. As a result, this medication helps staph infections and other illnesses caused by bacteria because it also works on gram-positive bacteria.
According to research on skin infections, healthy skin has low levels of LL-37, but when pathogens infiltrate the body, those levels rapidly rise. In addition, other proteins like human beta-defensin 2 work well with this peptide to fight infection.
Regeneration of Tissue
LL 37 peptide regulates the body’s balance of pro-and anti-inflammatory compounds in addition to being antimicrobial. Scientists say it’s challenging to strike a balance for both inflammation and tissue repair. To combat pathogens, the body needs inflammatory responses. However, these same inflammatory reactions can also prevent proper healing, cause scar tissue formation, and even lead to autoimmune conditions in some cases. Thanks to its impacts on macrophages – the cells responsible for inducing inflammation once pathogens invade the body – the LL-37 treatment supports a healthy balance between inflammation and healing.
LL-37 has also been shown in clinical trials to help treat wounds caused by P. aeruginosa and S. aureus by inhibiting the formation of biofilms. In addition, it can remove bacteria due to its antibiofilm properties and its connections with fibroblasts and keratinocytes, promoting wound healing.
Diseases Caused by Inflammation
Aside from its antimicrobial properties, LL37 has been shown to reduce inflammation in various other diseases, including Lupus, Arthritis, and Periostitis. According to research, the immune system is modulated by ll-37, which increases IL-18 and IFN-alpha production, changes neutrophils, and lowers levels of atherosclerotic plaques.
Research shows that LL 37 promotes immune system balance and prevents the risk of overactivity when an infection occurs by having homeostatic effects.
As a result, experts believe that LL-37 could help control autoimmune disease inflammation. LL-37 was once thought to be the source of inflammation, but new research shows that it may be a good remedy for autoimmune diseases.
People with arthritis may find relief from their symptoms by taking LL-37. The peptide was found in high concentrations in arthritic joints in studies involving rats. Because ll 37 decreased the body’s inflammation, this was the case.
It was also discovered in a study involving mice that LL-37 protects collagen from being damaged by the inflammation that occurs during arthritis. Furthermore, injections of LL-37 directly into the diseased joints have been shown to lessen the symptoms. As a result, scientists believe that LL 37 has anti-arthritic properties due to the high concentrations of the compound found in inflamed tissues. In addition, studies have shown that the peptide controls inflammation caused by interleukin-32, a molecule with solid ties to arthritis.
According to the research, upregulation of toll-like receptor 3 has also been linked to an aggravation of arthritis. On the other hand, TLR4 can be bound by LL-37 therapy, which promotes anti-inflammatory effects.
Chronic Obstructive Pulmonary Disease
Clinical trials have shown that LPS can be found in a wide range of organisms. Toxic amounts cause healthy lung tissue to produce, but they do not protect against respiratory diseases like asthma or COPD. Toxic dust syndrome may one day be treated with an LL-37 research peptide.
According to research on the effects of the LL-37 peptide on lung disease, the peptide promotes the proliferation of epithelial cells and healing wounds. Blood vessel growth is required to transport nutrients to new tissue and keep it healthy because airway epithelial cells attract them.
LL-37 has no known side effects, according to research.
Molar mass: 4493.342 g/mol
Unit Quantity: 1 Vial
Appearance: White Powder
Peptide Purity: >99%